Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease
NCT ID: NCT06873334
Last Updated: 2026-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2/PHASE3
120 participants
INTERVENTIONAL
2025-05-27
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study includes men and women aged 25 and older who have HD confirmed by genetic testing and meet certain requirements for physical ability and independence.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod
NCT02215616
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
NCT01590888
A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)
NCT05358717
Efficacy and Safety on SOM3355 in Huntington's Disease Chorea
NCT05475483
Pilot Study of Minocycline in Huntington's Disease
NCT00277355
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
SKY-0515 is designed to reduce mHTT protein levels by lowering of HTT messenger RNA (mRNA) through a splicing mechanism, leading to a decrease in both wild-type and mutant forms of HTT protein. Additionally, the drug lowers postmeiotic segregation 1 (PMS1) protein, which plays a role in somatic CAG repeat expansion-a key driver of HD progression. In early studies, SKY-0515 has reduced HTT and PMS1 mRNA levels in a dose-dependent manner, with favorable safety and tolerability profiles in healthy volunteers.
This study is a randomized, double-blind, placebo-controlled, trial conducted at multiple sites. Participants must be aged 25 or older, have genetically confirmed HD (CAG repeat length ≥ 40), and meet specific functional and motor criteria. They will be assigned randomly to one of four treatment arms (three doses of SKY-0515 and one placebo group) in a 1:1:1:1 ratio.
The study is composed of three periods:
1. Screening Period (up to 4 weeks): Participants will undergo eligibility assessments.
2. Double-Blind Treatment Period (12 months): Participants will take SKY-0515 or a placebo once daily and undergo regular clinic visits for monitoring. Safety and efficacy will be evaluated through blood tests, imaging (MRI), and clinical assessments, including the Unified Huntington's Disease Rating Scale (UHDRS).
3. Follow-Up Period (4 weeks): After completing treatment, participants will be monitored for any remaining effects.
An independent Data Safety Monitoring Board (DSMB) will oversee the trial to ensure participant safety.
This study will assess:
* Changes in levels of HTT proteins and other HD-related biomarkers.
* Effects on HD-related brain atrophy and clinical features.
* Long-term safety of SKY-0515.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1 (Active)
Dosage Level(s): Low dose once daily oral
SKY-0515
Study Drug Name (INN): SKY-0515 Type: Drug (small molecule) Dosage Level(s): Low, mid, high Route of Administration: Oral Dosage Frequency: Once daily Blinded Treatment Duration: 12 months
Use: Experimental Sourcing: SKY-0515 will be provided centrally by the Sponsor or subsidiary, or designee Packaging and Labeling: Study drug will be provided in blinded bottles labeled as required per country requirement. All packaging and labeling operations for the study drug will be performed according to current Good Manufacturing Practice for Medicinal Products and the relevant regulatory requirements.
2 (Active)
Dosage Level(s): Mid dose once daily oral
SKY-0515
Study Drug Name (INN): SKY-0515 Type: Drug (small molecule) Dosage Level(s): Low, mid, high Route of Administration: Oral Dosage Frequency: Once daily Blinded Treatment Duration: 12 months
Use: Experimental Sourcing: SKY-0515 will be provided centrally by the Sponsor or subsidiary, or designee Packaging and Labeling: Study drug will be provided in blinded bottles labeled as required per country requirement. All packaging and labeling operations for the study drug will be performed according to current Good Manufacturing Practice for Medicinal Products and the relevant regulatory requirements.
3 (Active)
Dosage Level(s): High dose once daily oral
SKY-0515
Study Drug Name (INN): SKY-0515 Type: Drug (small molecule) Dosage Level(s): Low, mid, high Route of Administration: Oral Dosage Frequency: Once daily Blinded Treatment Duration: 12 months
Use: Experimental Sourcing: SKY-0515 will be provided centrally by the Sponsor or subsidiary, or designee Packaging and Labeling: Study drug will be provided in blinded bottles labeled as required per country requirement. All packaging and labeling operations for the study drug will be performed according to current Good Manufacturing Practice for Medicinal Products and the relevant regulatory requirements.
4 (Control)
Matching placebo once daily oral
SKY-0515 Placebo
Route of Administration: Oral Dosage
Frequency: Once daily
Blinded Treatment Duration: 12 months
Use: Experimental
Sourcing: SKY-0515 placebo will be provided centrally by the Sponsor or subsidiary, or designee
Packaging and Labeling: Study drug will be provided in blinded bottles labeled as required per country requirement. All packaging and labeling operations for the study drug will be performed according to current Good Manufacturing Practice for Medicinal Products and the relevant regulatory requirements
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SKY-0515
Study Drug Name (INN): SKY-0515 Type: Drug (small molecule) Dosage Level(s): Low, mid, high Route of Administration: Oral Dosage Frequency: Once daily Blinded Treatment Duration: 12 months
Use: Experimental Sourcing: SKY-0515 will be provided centrally by the Sponsor or subsidiary, or designee Packaging and Labeling: Study drug will be provided in blinded bottles labeled as required per country requirement. All packaging and labeling operations for the study drug will be performed according to current Good Manufacturing Practice for Medicinal Products and the relevant regulatory requirements.
SKY-0515 Placebo
Route of Administration: Oral Dosage
Frequency: Once daily
Blinded Treatment Duration: 12 months
Use: Experimental
Sourcing: SKY-0515 placebo will be provided centrally by the Sponsor or subsidiary, or designee
Packaging and Labeling: Study drug will be provided in blinded bottles labeled as required per country requirement. All packaging and labeling operations for the study drug will be performed according to current Good Manufacturing Practice for Medicinal Products and the relevant regulatory requirements
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* You must have Huntington's Disease confirmed through genetic testing, with a specific gene change (CAG repeat of 40 or more).
* Total Functional Capacity (TFC) score of 10 or more).
* Total Motor Score (TMS) of 6 or more).
* Independence Score (IS) of 70 or more).
* Women who can have children must have a negative pregnancy test before starting and use two types of birth control during the study and for 30 days after the last dose of the study drug.
* Men must agree to use birth control during the study and for 90 days after the last dose.
* You must agree to sign a consent form and follow the study's rules and schedule.
Exclusion Criteria
* You have a condition that interferes with protocol-specified assessments, like an implanted medical device or difficulty getting an MRI.
* You have cancer, except for some types of skin cancer, or a history of cancer in the last five years.
* You have severe allergies or have reacted badly to similar drugs in the past.
* You are taking medications or treatments that might interfere with the study.
* You've been in another study or taken experimental drugs in the last two months (or longer for some drugs).
* You have had any kind of gene therapy.
* You have a history of suicidal thoughts, severe depression, or have attempted suicide in the past year.
* Your liver function tests show significant abnormalities.
* You have tested positive for hepatitis B, hepatitis C, or HIV.
* You are pregnant, breastfeeding, or planning to become pregnant during the study.
25 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Skyhawk Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Masoud Mokhtarani, MD
Role: STUDY_DIRECTOR
Skyhawk Therapeutics, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
John Hunter Hospital
New Lambton Heights, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
The University of Queensland
Herston, Queensland, Australia
Flinders Medical Centre
Adelaide, South Australia, Australia
Calvary Health Care Bethlehem
Caulfield South, Victoria, Australia
The Royal Melbourne Hospital
Parkville, Victoria, Australia
The Perron Institute for Neurology and Translational Science (Perron Institute)
Nedlands, Western Australia, Australia
Huntington's Disease Association
Auckland, , New Zealand
Auckland City Hospital
Auckland, , New Zealand
Christchurch Neurology Trials Limited
Christchurch, , New Zealand
Wellington Hospital
Wellington, , New Zealand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yenni Lie
Role: backup
Principal Investigator
Role: backup
Related Links
Access external resources that provide additional context or updates about the study.
Skyhawk Therapeutics Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SKY-0515-004-ANZ
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.